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1. Introduction  
Diffuse gliomas are preferentially located in the subcortical or deep white matter of the 
cerebral hemispheres and are the most frequent CNS neoplasms accounting for 
approximately 60 per cent of all CNS tumors (CBTRUS 2011). This definition excludes the 
circumscribed and biological different pilocytic astrocytoma and pilomyxoid astrocytoma 
which are covered in a separate chapter in this book. Other rare distinct glial neoplasms 
with a favourable prognosis such as the subependymal giant cell astrocytoma of lateral 
ventricles and the pleomorphic xanthoastrocytoma of children and young adults also do not 
belong into the group of diffuse gliomas. Ependymomas indeed are diffuse growing glial 
neoplasms but are biologically different. Moreover they appear in a different population as 
astrocytic and oligodendroglial neoplasms. Because of space limitations the current chapter 
deals only with astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas. 
These tumors are grouped here under the umbrella term “diffuse gliomas”. They have a 
predilection for frontal and temporal lobes accounting together for more than two third of 
all cases. However diffuse astrocytomas may be seen in any other region of the brain 
including cerebellum and spinal cord (Louis et al., 2007a).  
Although serious advances in neuroimaging of these brain tumors have been made in the 
past, histopathologic evaluation of neurosurgically removed tumor specimens is still 
required for definite diagnosis of diffuse gliomas. These CNS tumors show an extensive 
variety of histologcial and cytological appearance making diagnosis somewhat difficult for 
those who are not familiar in working with brain tumors. The current chapter focuses on 
neuropathological features of the different types of diffusely infiltrating gliomas  based on 
the latest World Health Organization (WHO) classification of tumors of the nervous system. 
Core features and distinct pattern and variants are also introduced and illustrated. 
Immunohistochemistry and molecular biology have contributed to an improved 
classification and shown in some cases to be of prognostic value. The advantages and 
limitations of the most commonly used antibodies such as GFAP, WT1, MAP2, MIB-1, P53, 
IDH1R132H; NOGO-A are discussed in the current chapter. Molecular analysis of 1p19q 
codeletion, MGMT promoter methylation, Tp53 and isocitrate dehydrogenase mutations are 
presented in detail and their implications are discussed. 
2. Incidence and overview 
Regional incidences vary with generally higher number in developed countries and are 
estimated between 2.2 per million people for low-grade lesions (i.e. WHO grade II 
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neoplasms) and up to 4.6 per 100.000 people for glioblastoma (Ohgaki et al., 2005a). There is 
a strong correlation between age of presentation and histological tumor grade. The mean 
age of diagnosis for diffuse astrocytoma grade II WHO is 39 years, for anaplastic 
astrocytomas grade III WHO is 45 years and 61 years for glioblastoma grade IV WHO. The 
mean age for oligodendroglioma is 43 years, for anaplastic oligodendrogliomas grade III it is 
47 years. Mean age for oligoastrocytomas is 40 years, for anaplastic oligoastrocytomas is 44 
years (Louis et al., 2007a). A similar age distribution has been observed in our institution. 
Less than 10% of astrocytic and less than 2% of oligodendroglial tumors develop in the 
pediatric age group. Thus, the pathologist should always take patients age into mind when 
considering possible differential diagnoses. There is a slight predominance of males (Ohgaki 
et al., 2005b) but in contrast to meningiomas or germ cell tumors this is not of diagnostic 
relevance. Higher socioeconomic status is also a risk factor.  
The histologic subtypes are not evenly distributed. Diffuse astrocytomas represent 5-10%, 
anaplastic astrocytomas approximately 10% and glioblastomas between 75-85 per cent of all 
astrocytic neoplasms (CBTRUS, 2011). This can be explained by the fact that glioblastomas 
are a heterogenous group of tumors with distinct genetic features but similar morphology. 
Diffuse astrocytomas show a tendency to progress to a more malignant phenotype during 
disease progression within 6-8 years, ending finally as secondary glioblastomas, (10-15% of 
all glioblastomas). However there is no biomarker that can predict the time to progression in 
individual patients. The majority of glioblastomas develop without a precursor lesion (“de 
novo”) and are genetically distinct from the secondary glioblastomas (Ohgaki et al, 2007). In 
primary glioblastomas several activated oncogenic pathways are known, but all share a 
similiar dismal prognosis. Oligodendroglial tumors account for 5-6% of all gliomas and in 
this group 70% are diagnosed as grade II oligodendrogliomas and 30% as grade III 
anaplastic oligodendrogliomas (CBTRUS, 2011). While there is no doubt that 
oligodendroglioma undergo a similar malignant tumor progression as astrocytic neoplasms, 
there is still debate about how much of these truly develop into glioblastomas. Because of 
divergent classification criteria true estimates for mixed gliomas vary between 1 and 10% of 
all gliomas. According to the more stringent CBTRUS  criteria, only 2% of all gliomas meet 
the criteria for a mixed oligodendroglial – astrocytic neoplasm (CBTRUS, 2011). 
2.1 General grading of diffuse gliomas 
In 1979 the World Health Organization issued a publication for classification of tumors of 
the central nervous system which has been updated lastly in 2007. This included a grading 
scheme based on malignancy behaviour of the tumors. Grading of diffuse gliomas is 
performed in a four-tiered score ranging from grade I to grade IV, the latter bearing the 
worst prognosis. Histological factors that influence grading are nuclear atypia, cellularity, 
mitosis, necrosis and endothelial proliferations. Among diffuse gliomas grade II is assigned 
to diffuse astrocytoma, oligodendroglioma and oligoastrocytoma. Grade III neoplasms 
include anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic 
oligoastrocytoma. Grade IV is reserved for glioblastoma. This score is used to separate the 
histologic continuum of diffuse gliomas. 
3. Astrocytoma 
3.1 Macroscopy 
The invaded CNS tissue is usually enlarged, but main anatomical structures remain 
relatively intact. The overlying cerebral cortex might be affected with a blurred gray-white 
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junctional zone. Tissue from this area instead of the deeper white matter might be not 
diagnostic or carries the risk of undergrading the tumor. The fixated tissue appears 
yellowish to gray and may be of varying texture, either softer or firmer than the 
surrounding normal appearing brain. Larger cysts are uncommon but when present are 
usually filled with a clear fluid. In cases with extensive microcystic formations of the tumor, 
a gelatinous appearance is present. Calcifications within the tumor is not the role. In spinal 
cord, cystic lesions may extend from the tumor poles. 
3.2 Histology 
Astrocytomas might display a wide range of cytologic and histologic features so that some 
autors even state that “astrocytomas are best defined as infiltrating gliomas that cannot be 
classified as oligodendrogliomas” (Burger & Scheithauer 2007). One important diagnostic 
marker is the hypercellularity of the CNS tissue. The number of tumor cells is usually 
slightly increased with a cellularity of two to five times than normal and the distribution of 
cells is irregular. Neoplastic astrocytes usually exhibit irregular elongated, hyperchromatic 
nuclei lacking a perinuclear halo with often minimal fibrillar cytoplasm (“naked nuclei”). 
The tumor cells lie between myelinated axons which can be visualized with luxol fast blue 
stains. In some cases there is a prominent pink cytoplasm with short stout processes and 
eccentrically placed nuclei, a so called “gemistocytic appearance”. These tumors are prone 
to perivascular lymphocytic cuffs which are also seen in glioneuronal tumors (Takeuchi et 
al., 1976). Nuclei in gemistocytic variants are more rounded and less irregular and might 
show micronucleoli. Since almost all astrocytomas exhibit some gemistocytic tumor cells, a 
cut off of more than 20% gemistocytes has been proposed for the gemistocytic variant of 
astrocytoma (Tihan et al., 2006). Tumor margins in astrocytomas are rarely discernible. The 
neoplastic astrocytes rest on a fibrillary background which often shows some microcystic 
changes and increased density of cellular processes. These microcavities are usually absent 
in reactive gliosis. Cases with extensive mucoid degeneration and rarity of glial processes 
are designated as protoplasmatic  astrocytomas. All three morphologies fibrillar, 
gemistocytic and protoplasmatic are considered histological variants of diffuse 
astrocytomas. Since a different clinical outcome for these is not firmly established some 
authors rather consider these as divergent patterns of differentiation (Louis et al.,  2007b).  
Compared to diffuse astrocytomas, anaplastic astrocytomas exhibit increased cellularity, 
distinct nuclear atypia and mitotic activity but lack the micovascular proliferation and 
necrosis of glioblastomas. Multinucleated tumor cells are often diagnostic for a grade III 
lesion but not required for their diagnosis. One should also be aware of possible previous 
radiation therapy of the tumor leading to an increase of cell pleomorphism together with a 
decrease of mitotic activity (Gerstner 1977).  
The original St. Anne-Mayo grade system did not allow mitoses in a low-grade lesion. 
Current criteria suggest that presence of zero or one mitosis do not alter survival and thus is 
still compatible with a WHO grade II neoplasm (Giannini et al., 1999). Unfortunately the 
WHO classification allows for a broad range of interobserver variability in borderline cases 
of low-grade gliomas, as presence of mitotic activity has to be interpreted in regard to the 
total sample size (Louis et al., 2007). In small specimens such as stereotactic biopsies a single 
mitosis suggests at least a grade III lesion but in larger specimens the presence of a single 
mitosis is not sufficient (Giannini et al., 1999). Cases with low cellularity of astrocytic tumor 
cells but exhibiting several mitoses should be considered as grade III or IV lesions. Diffuse 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
202 
astrocytomas (WHO grade II) have normal appearing vessels and a vessel density that is 
only slightly greater than in normal human brain. Compared to grade II lesions the vessel 
density increases further in grade III astrocytomas (Brat et al., 2001). 
 
 
Fig. 1. Histology of diffuse astrocytoma: HE stains of (A) fibrillary astrocytoma, (B) 
protoplasmatic astrocytoma and (C) gemistocytic astrocytoma. The proliferation in these 
tumors, as determined by MIB-1 nuclear immunoreactivity (D) is low (1-2%). Strong, 
consistent GFAP expression in neoplastic astrocytes (E). IDH1 mutations are found in up to 
70% of these tumors, the most common R132H mutation can be detected 
immunohistochemically (F). 
Differential diagnosis also includes reactive changes of the CNS. In astrocytic neoplasm, 
tumor cells are morphologically similar but less evenly distributed than reactive cells which 
are in different stages of activation. In addition reactive astrocytes show longer stellate 
processes. It is also important to recognize entrapped neurons and differentiate these from 
the more pleomorphic or even multinucleated neuronal tumor cells of a ganglioglioma. 
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Ventricular tumors with bizarre giant cells but low mitotic activity are often subependymal 
giant cell astrocytomas (WHO grade I). 
3.3 Immunohistochemistry 
Astrocytomas show an expression of glial fibrillary acidic protein in tumor cells (Yung et al,. 
1985). Especially the gemistocytic tumor cell cytoplasm and rare interdispersed Rosenthal 
fibers show a strong immunoreactivity for GFAP (Tascos et al., 1982). In addition the 
fibrillary neuropil displays almost always shows a diffusely positive background. Fibrillary 
astrocytes often show a small perinucelar rim, while interdispersed small round cells might 
be GFAP-negative. In independent studies all examined diffuse astrocytomas, were at least 
focally positive for GFAP (Cosgrove et al., 1986, Waidelich et al., 2010). Astrocytomas also 
express consistently S-100 and vimentin (Tabuchi et al., 1982, Yung et al., 1985). While S-100 
is also present in the nuclei, Vimentin is often absent in distant cell processes. The 
malignancy-associated expression of WT1 is less intense than in high-grade astrocytic 
lesions (Hashiba et al., 2007, Rushing et al., 2010) but usually more prominent as in reactive 
lesions or oligodendrogliomas. WT1 is expressed in 52% of all diffuse astrocytomas, but 
tumors with more than 75% positive WT1 cells should prompt the diagnosis of a high grade 
glioma (Schittenhelm et al., 2009). A single study demonstrated that oligodendroglia-
associated marker Nogo-a is absent in grade II and III astrocytomas (Kuhlmann et al., 2008). 
Caution should be employed when using epithelial antigens, such as cytokeratins and 
epithelial membrane antigen for differential diagnosis of carcinomas, as variable expression 
of these markers have been observed in astrocytomas (Franke et al.,1991; Ng et al.,1989). A 
bcl-2 expression in diffuse astrocytomas is more prominent than in reactive lesions and 
frequently seen in gemistocytic tumor cells (Hussein et al., 2006). 
The microtubuli-associated protein 2 which has once been considered as a neuronal marker 
is expressed in 92-97% of astrocytomas (Wharton et al., 2002). Cytoplasmic staining is 
preferentially seen in the larger, more pleomorphic, tumour cells and expression is generally 
more intense in high-grade lesions than in astrocytomas grade II. Some authors propose, 
that presence of MAP2-positive ramifying cytoplasmic processes aids in differentiating 
astrocytomas from oligodendogliomas where MAP2 is expressed in a capped fashion 
highlighting the rounded cells (Blümcke et al., 2004). MAP2 might also help to distinguish 
astrocytic tumors from ependymal neoplasms which show usually only solitary MAP2-
positive cells in one third of cases examined.  
Expression of p53 is seen in 72% of diffuse astrocytomas and more prominent in 
gemistocytic tumor cells and younger patients (Vital et al., 1998). However we have 
observed p53 in up to 63% of reactive lesions. The phospho-histone H3 marker might be 
useful to detect mitoses in tumor specimens with a proposed cutoff of 4/1000 between 
grade II and grade III astrocytomas (Colman et al., 2006). MIB-1 tumor proliferation is 
usually between 2-3%, rarely exceeding 4% (Sallinen et al., 1994). In protoplasmatic 
variants the MIB-1 proliferation index is usually lower than in other tumor variants 
(Prayson et al., 1996). The MIB-1 proliferative activity of astrocytomas grade III usually 
ranges between 5-10% and there is an overlap on both sides to grade II and grade IV 
lesions. Rare astrocytoma cases may show focal islands of small oligodendrocyte-like cells 
with  immunoreactivity for synaptophysin and NeuN between conventional glial tumor 
cells (Barbashina et al., 2007).  
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
204 
 
Fig. 2. Anaplastic astrocytomas are histologically characterized by (A) increased cellularity, 
(B) nuclear pleomorphism, (C) presence of several mitoses. Gemistocytic tumors (D) are 
prone to undergo a more rapid tumor progression. Immunohistochemistry shows increased 
MIB-1 prolifation index (E). Extensive p53 nuclear immunoreactivity (F) is more frequent in 
astrocytomas than oligodendrogliomas or glioblastomas. GFAP (G) also marks the 
elongated tumor cell processes. Anaplastic astrocytomas have a considerably higher 
presence of MAP2 positive tumor cells (H) than grade II astrocytomas. 
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3.4 Electron microscopy 
Utrastructurally astrocytomas contain abundant 7 to 11nm sized not always parallel 
aligned intermediate filaments independent of fibrillary, gemistocytic or protoplasmic 
phenotype of the tumor cells (Duffell 1963). Cells contain dilated cisterns of 
endoplasmatic reticulum, lysosomes and lipid deposits. Eosinophilic granular bodies 
display as dense osmiophilic masses between intermediate fibrils. The ultrastructural 
picture of glioblastomas is similar. 
4. Glioblastoma 
4.1 Macroscopy 
The most malignant astrocytic glioma widely known by its acronym “GBM” was orginally 
designated as “glioblastoma multiforme” because of extensive variability of tumor 
histologies. However, individual tumors can also appear quite monorpous on histology. 
For this reason the “multiforme” is no longer used by the current WHO classification 
(Burger & Scheithauer, 2007). In our institution we prefer to use the term “multicentric” 
for single tumors with radiologically or macroscopically separate lesions and the term 
“multifocal” for true multiple lesions for which no histological continuum between the 
tumor centers exists. Common tumor spreading routes include fornix, corpus callosum, 
anterior comissure and radiation optica because of the high affinity of tumor cells for 
myelinated structures (Burger et al.,  1983). Tumors that reach the dura show often 
marked desmoplasia leading to a firm texture resembling gliosarcoma or meningioma 
(Stavrinou et al., 2010).  
The necrotic center of the tumor is often surrounded by a gray rim and varying yellowish-
grayish texture of the surrounding white matter. Black hemorrhagic streaks and thrombosed 
veins are typically for a grade IV lesion. Symmetric tumors spreading over the corpus 
callosum are called “butterfly gliomas”. Glioblastoma tumor borders are usually diffuse but 
rare cases (especially giant cell pseudoepithelial glioblastomas) can be very circumscribed 
mimicking a carcinoma metastasis. 
4.2 Histology 
The prominent eosinophilic cytoplasm of pleomorphic tumor cells with small fibrillary 
zones indicates astrocytic heritage of the glioblastoma but this is not the rule for all tumors. 
Marked nuclear atypia and elevated mitotic activity is common. Either microvascular 
proliferations or necrosis or both are required to secure the diagnosis. Tumor appearance 
can be so heterogenous that diagnosis is often based on tissue patterns rather than 
individual tumor cell morphology. Occasionally perinuclear halos may resemble 
oligoendrogliomas, however glioblastoma tumor nuclei lack the monotony roundness of 
true oligodendrogliomas. Small cells with little cytoplasm can appear so monomorphous 
that small cell glioblastomas mimic anaplastic oligodendrogliomas. Small undifferentiated 
tumor cells intermingled with gemistocytes are more likely seen in secondary glioblastomas 
developing from gemistocytic astrocytomas. Some tumors may show prominent 
perivascular rosettes resembling anaplastic ependymomas but usually lack the more 
uniform roundness of ependymal tumor cells. Tumor cells can be elongated and arranged in 
fascicles so that at the first view sarcoma comes into mind.  
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Fig. 3. Glioblastomas are defined through microvascular proliferations (A) and 
pesudopalisading necroses (B). The tumor is mitotically active (C) and may show a high 
degree of anaplasia (D). Glioblastoma cell composition can be so heterogenous with adenoid 
epithelial metaplasia (E), small cell component (F), focal oligodendroglial differentiation (G) 
or granular cells (H) in some cases. 
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Morphologic variants include granular cell astrocytoma which is characterized by large, 
PAS-positive cells with a degenerative granular lysosomal content. These look similar to the 
benign granular cell tumor of the pituitary stalk (Schittenhelm et al., 2010). Another variant 
is the often subcortical located giant cell glioblastoma showing multinucleated giant cells in 
more than 50% of tumor cells that can be associated with reticulin deposits (Palma et al., 
1989). These tumors need to be distinguished from the more benign subependymal giant cell 
astrocytomas or pleomorphic xanthoastrocytoma. Another variant contains a biphasic 
pattern of alternating reticulin-free glial and reticulin-containing mesenchymal deposits and 
are aptly named gliosarcomas (Louis et al., 2007a). These tumors account for 2% of all 
glioblastomas (Meis 1991). Metaplastic transformation can be so extensive that chondroid 
and osseous formations in gliomas are possible (Schittenhelm et al., 2007). Furthermore 
gliomas can show focal areas of epithelial differentiation that ranges from positive 
immunreactivity of epithelial antigens to adenoid or squamous formations leading to 
misdiagnosis of carcinoma (Rodriguez et al., 2008). Rare cases may show a melanotic 
differentiation (Jaiswal et al., 2010). 
In average 3 pseuopalisading necroses are present in a glioblastoma specimen (Brat et al., 
2004). Pseudopalisading cells are usually less proliferative and exhibit higher rates of 
apoptosis due to hypoxic conditions but are usually without a prominent inflammatory 
infiltrate. More than half of the palisades show a central vascular lumen, in about twenty 
percent intravascular thrombosis is also seen (Brat et al., 2004). Vascular proliferations may 
be present throughout the tumor but there is a tendency for these structures to accumulate 
in the peripheral region of high cellularity corresponding to the contrast-enhancing ring 
seen in radiological images (Louis et al., 2007a). Tumor vessels in glioblastoma have an 
increased density and show hyperplasia (Brat et al., 2001). Tumor vessel arrangement in a 
garland-like fashion is not uncommon. Vascular proliferation in form of glomeruloid bodies 
in glioblastomas is more frequently than in tumors from any other organ system (Plate et al., 
1999).  
Infiltrative growth is mostly characterized by small undifferentiated cells growing along 
axonal structures in the white matter or along the brain surface and blood vessels. These are 
designated as ‘secondary structures of Scherer’ (Scherer, 1938). In the spinal cord, tumor 
cells might extend into the subarachnoid space (Burger & Scheithauer, 2007). Apoptosis of 
tumor cells is not a major feature but most prominent in areas of pseudopalisading necrosis. 
4.3 Immunohistochemistry 
The immunoprofile of glioblastomas is in many ways similar to astrocytomas. The vast 
majority of glioblastomas express the glial markers GFAP and EAAT1 (Waidelich et al., 
2010) but these antigens may occasionally lacking (especially in small glioblastomas). S-100 
immunostaining is then helpful to indicate a glial origin of the neoplastic cells. Strong MAP2 
immunoreactivity is seen in 90% of glioblastomas (Blümcke et al., 2004). Vimentin 
immunoreactivity is very unspecific. Diffuse growth of gliomas can be supported by 
identifying axons with neurofilament stains within the tumor, but extensive neurofilament 
immunoreactivity of the tumor should prompt the diagnosis of an (anaplastic) 
ganglioglioma. In gliosarcomas, GFAP is lacking in sarcomatous areas. A complementary 
reticulin staining pattern in these tumors is diagnostic. The proliferation varies greatly, 
usually 15-25% of the nuclei are MIB-1 positive, but tumors with small cell morphology can 
show up to 90% proliferating cells. Tumors with previous radiation or gemistocytic 
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morphology may show little proliferating activity. Because of inconsistent laboratory 
techniques and varying evaluation methods, MIB-1 immunoreactivity has no established 
cutoffs between low-grade and high-grade lesions. WT1 expression is consistently expressed 
in glioblastomas (Schittenhelm et al., 2009). In our experience expression is similar in 
primary and secondary tumors but expression can be reduced in recurrent tumors. In 
addition there is evidence that tumors that contain a Tp53 mutation show reduced WT1 
levels compared to Tp53 wild type glioblastomas (Clark et al., 2007). IDH1 R132H antibody 
expression is found in 4% of primary and in 71% of secondary glioblastoma (Capper et al.,  
2010). Tp53 immunoreactivity is less present than in astrocytomas but can be considerably 
high in giant cell glioblastomas. Microglial markers such as CD68 are regularly found in 
glioblastomas and can be very extensive in tumors with granular cell component and need 
to be distinguished from demyelinating lesions. Cytokeratin expression in glioblastomas 
(especially in giant cell glioblastomas and glioblastomas with true epithelial metaplasia) is 
an important diagnostic pitfall (Rodriguez et al., 2008). Dot-like EMA immunoreactivity is 
less frequently observed in glioblastomas than in ependymomas, where usually more than 5 
EMA-positive dots per high-power field are seen (Hasselblatt & Paulus 2003). 
Immunohistochemistry of EGFR wild type protein is more prominent in primary 
glioblastomas as in grade II or III gliomas (Simmons et al. 2001). 
5. Oligodendroglioma 
5.1 Macroscopy 
Like all other diffuse growing tumors, oligodendroglioms show diffuse borders. The tumors 
are usually soft and have a grey to pink color. They may appear hemorrhagic and / or 
calcified but this is not a specific feature for oligodendrogliomas   Superficial growth can 
expand the cortical grey matter. The anaplastic forms lack a central necrosis typically for 
glioblastoma but may show focally smaller necroses. Rare disseminating cases may grow as 
superficial gelatinous mass extending along the spinal cord (Mittelbronn et al.,  2005). 
5.2 Histology 
In contrast to astrocytomas, oligodendrogliomas are dominated by histologic monotony of 
the round to oval shaped tumor cells which are best seen in smears. Nuclei have a bland 
chromatin and prominent nucleoli. The very characteristic perinuclear halo – a fixation 
artefact resulting from autolytic water absorption – is absent in frozen sections or specimens 
that have been quickly processed resulting from a short fixation time. Delicate branching 
capillaries and tumor calcifications that also may affect tumor vessels are more frequent in 
oligodendrogliomas than in other CNS tumors. Overun cortical areas show a perineuronal 
satellitosis of the tumor cells and tumor cells may concentrate along subpial structures. In 
addition cortical structures show often smaller microcystic changes.  
Anaplastic oligodendrogliomas show increased nuclear pleomorphism that is mostly 
restricted to focal areas and increased mitotic activity compared to grade II lesions. Some 
authors prefer a mitotic cutoff of 6 mitoses per 10 high power fields to discriminate between 
grade II and grade III lesions (Giannini et al., 2001). Focal elevated cellular areas as nodules 
do not warrant tumor designation as a grade III lesion in absence of other anaplastic 
features. In contrast to astrocytomas where endothelial proliferations lead to the diagnosis 
of glioblastoma, vascular proliferations or extended vascular hyperplasia are typical for 
anaplastic oligodendroglioma grade III. In addition smaller areas of necrosis may be 
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Fig. 4. Oligodendrogliomas show a typical honeycomb pattern (A). Tumor borders can be 
discrete infiltrative (B). Anaplastic oligodendroglioma with endothelial proliferations (C) 
and increased MIB-1 proliferation index (D). Oligodendroglial tumors typically exhibit a 
marked perinuclear MAP2 immunoreactivity (E) and show far less WT1 immunopositive 
cells (F) than astrocytomas. Mixed oligodendroglioma-astrocytoma can present either as 
true biphasic tumors (G) or as strongly intermixed (H) as in this anaplastic oligoastrocytoma 
with extensive mitotic activity. 
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present but not typically in the pseudopalisading forms of glioblastoma. The current WHO 
classification however explicitly allows presence of pseudopalisading necroses in anaplastic 
oligendrogliomas and thus weakens a sufficient discrimination to glioblastomas with 
oligodendroglial differentiation. Anaplastic oligodendrogliomas may contain smaller cells 
with pink cytoplasm and eccentric placed nuclei, so called minigemistocytes and areas with 
increased fibrillar background and plump process-bearing gliofibrillary oligoendrocytes. 
These eosionophilic cells are seen more often in grade III than grade II oligodendrogliomas. 
Finally some oligodendroglioma tumor cells may have sharp delineated borders resembling 
epitheloid differentiation. In the tumor edges severeal astrocytic cells might be present but 
unless clearly neoplastic in nature their presence does not warrant the diagnosis of mixed 
oligoastrocytoma. Focally parallel tumor cell growth may resemble polar spongioblastomas 
(Louis et al., 2007). Rare cases of oligodendrogliomas may show focally neuopil islands that 
have to be distinguished from neurocytomas. Tumor cells with signet-ring cell morphology 
have also been described in oligodendrogliomas (Kros et al., 1997). 
5.3 Immunohistochemistry 
There is no distinct single antibody availabe to discriminate reliably between 
oligodendroglial and astrocytic neoplasms. It is adviseable to use a panel of different 
antibodies for which expression patterns in these neoplasms has been extensively studied. 
In our institution we stain routinely gliomas for MIB1, GFAP, MAP2, WT1 and IDH1 
R132H. Expression of GFAP is usually absent in tumor cytoplasm of oligodendroglia, 
however in our daily practice sometime there is ample overlapping of GFAP-positive 
fibrillary neuropil background. In addition minigemistocytes and gliofibrillar 
oligodendrocytes are usually positive for GFAP. MAP2 is constantly expressed in 
oligodendrogliomas, but also found in 92% of astrocytomas and glioblastomas (Blümcke et 
al., 2004). A perinuclear “capped” expression pattern is more typical for 
oligodendrogliomas, while in astrocytomas the elongated cell processes are also 
immunoreactive for MAP2. WT1 in oligodendrogliomas is usually restricted to single WT1-
positive tumour cells or completely absent while WT1 is strongly expressed in 83-92% of 
high grade astrocytic lesions (Schittenhelm et al., 2009). Therefore, in our experience, 
expression of WT1 in more than 50% of tumor cells indicates either astrocytoma or 
oligoastrocytoma rather than oligodendroglioma. Nogo-A is found in 71% 
oligodendrogliomas and 24% glioblastomas but is absent in astrocytomas (Kuhlmann et al., 
2008). While Olig2 immunoreactivity  is slightly stronger in oligodendrogliomas is also 
constantly seen in other glial neoplasms (Ligon et al., 2004). Alpha internexin is found in 45-
59% of oligodendrogliomas ans seems to be associated with an 1p19q codeletion (Ducray et 
al., 2011). Positive IDH1-R132H immunoreactivity is so frequent in oligodendroglial tumors 
(up to 91% in grade II and 94% in grade III lesions) that this marker is very useful to 
discriminate oligodendrogliomas from other brain tumors with oligodendroglial 
morphology (Capper et al., 2011). Diffuse immunoreactivity of p53 is uncommon in 
oligodendroglial tumors but when present indicates an intact chromosomal 1p arm (Hirose 
et al., 2010). Oligodendrogliomas with neurocytic differentiation may show synaptophysin-
positive neuropil islands and rosettes but usually lack the NeuN nuclear immunoreactivity 
of neurocytomas. In addition presence of IDH1 or IDH2 mutation strongly favors diagnosis 
of oligodendroglioma over neurocytoma (Capper et al., 2011). 
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5.4 Electron microscopy 
The short tumor cell processes contain microtubuli and ocassionally pericellular spiral 
laminations but usually lack the abundant intermediate filament of astrocytic tumor cells 
(Min et al., 1994). Electron microscopy is not used in regular routine practice as combined 
data from histology, immunistochemistry and molecular pathology is usually sufficient 
enough do diagnose an oligodendroglioma or mixed glioma. 
6. Oligoastrocytoma 
Criteria for mixed astrocytomas / oligodendrogliomas are weakly defined. Not 
surprisingly interobserver variaibility is great ranging from 9-80% as seen in a study on 
155 tumors that were initially classified as oligoastrocytomas (Fuller et al., 2003). 
Macoscopically these tumors are similar to other diffuse grade II or grade III lesions. 
Histological diagnosis of oligoastrocytoma requires that both astrocytic and 
oligodendrogial neoplastic tumor cells are present in the same tumor. These may appear 
biphasic as two distinct tumor areas or more commonly as intermingled tumor. The 
minimal amount to which one tumor component has to be present is unfortunately not 
properly defined. Some authors are satisfied when one single high power field has either 
astrocytic or oligodendroglial tumor cells, other authors request at least a minimum of 
50% neoplastic astrocytes. Separation of astrocytes and oligodendrocytes is not always 
possible. Every pathologist has seen tumor cells that have features of both lineages. It is 
important however to distinguish minigemistocytes and gliofibrillar oligodendrocytes in 
oligodendrogliomas from astrocytes, as they do not warrant the diagnosis of 
oligoastrocytoma. Single mitoses are compatible with a grade II oligoastrocytoma, 
however in our institution we have an relaxed approach, when mitoses are increased in a 
distinct oligodendroglial compartment only. Anaplastic oligoastrocytomas show 
increased nuclear atypia, elevated cellularity and abundant mitoses. Microvascular 
proliferations are frequent in grade III oligoastrocytomas. Discrimination of anaplastic 
oligoastrocytoma from  glioblastomas with oligodendroglial differentiation is especially 
difficult, as WHO criteria allows pseudopalisading necroses to be present in 
oligoastrocytic tumors. In our institution decision is based on whether necroses are 
present in astrocytic tumor parts indicating a glioblastoma or is limited to 
oligodendroglial tumor parts indicating anaplastic oligoastrocytoma. Like histology, 
immunhistochemistry results are very mixed and represent the immunophenotype of 
neoplastic astrocytes or oligodendrogytes as discussed in their sections. Grade II tumors 
have a MIB-1 proliferation index usually less than 6% (Deckert et al., 1989). 
7. Molecular biology 
Because of their favourable prognostic value 1p19q codeletion, MGMT promoter 
methylation and isocitrate dehydrogenase mutations are considered important clinical 
biomarkers for diffuse gliomas. In addition p53 is useful for diagnostic purposes. These 
markers are requested with increasing frequency and are discussed in detail below. Even 
when the diagnosis of a specific glioma type is readily apparent in histological stains, 
pathologist need to take care, that sufficient tissue is available for future molecular 
analysis. 
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7.1 Tumor protein 53 mutations 
Since Tp53 mutations are broadly distributed, exons 5-8 need to be screened by single-
strand conformational polymorphism analysis followed by direct sanger sequencing of 
samples exhibiting mobility shifts. In unremarkable cases, sequencing analysis is usually 
extended to exons 4, 9 and 10. Because of these efforts, Tp53 molecular analysis is not part of 
routine diagnosis unlike p53 immunostaining. A Tp53 mutation in diffuse astrocytomas 
grade II WHO is observed in 52-60% of the tumors, while Tp53 mutations are present in 35-
44% of oligoastrocytomas and in 10% oligodendrogliomas (Okamoto et al., 2004, Kim et al., 
2010). Especially astrocytomas with gemistocytic tumor cell morphology may contain Tp53 
mutations in up to 82% of tumors (Watanabe et al., 1998). Since Tp53 mutations are acquired 
early, their frequency does not increase much further during tumor progression (Watanabe 
1997). In pediatric glioblastomas, Tp53 mutations were found in 60% of tumors examined 
(Srivastava et al., 2010). Grade II WHO diffuse astrocytomas may show in 49% a combined 
TP53 mutation and IDH1 or IDH2 mutation (Kim et al., 2010). A Tp53 mutation without 
associated IDH1/2 mutation is rare (3%), thus indicating that IDH mutations occur at an 
earlier stage of tumorgenesis.  
7.2 Isocitrate dehydrogenase mutations 
The NADP-dependent enzymes IDH1 and IDH2 catalyze the conversion from isocitrate in 
alpha-ketoglutarate. Mutations of  the catalytic center in  gliomas result in accumulation of 
the oncogenic metabolite D-2-hydroxyglutarate (Dang et al., 2009). It is thought that the 
reduced NADPH levels in IDH mutated gliomas could sensitize tumors to radiation and 
chemotherapy (Bleeker et al., 2010). The frequency of IDH mutations is high in diffuse 
astrocytomas, anaplastic astrocytomas and secondary glioblastomas evolving from these 
precursor lesions, while presence of IDH mutations is seen in only 3-7% primary 
glioblastomas (Hartmann et al., 2009). The vast majority of IDH1 mutations are point 
mutations leading to a distinct amino acid substitution on codon 132 (Arg132His) for which 
an specific antibody has been developed (Capper et al., 2010). The other amino exchange 
mutations can be detected either by direct sanger sequencing or restriction-endonuclease 
based PCR (Meyer et al., 2010).  
IDH1 mutations are found in 59-88% diffuse astrocytomas, 50-78% anaplastic astrocytomas 
and 50-88% secondary glioblastomas, IDH2 mutations are present in 1-7% diffuse 
astrocytomas, 1-4% anaplastic astrocytomas and seem to be absent in secondary 
glioblastomas (Bourne et al., 2010). The rate of IDH2 mutations in oligodendrogliomas is 
higher as in astrocytomas (4-8% in oligodendrogliomas grade II and grade III, 1-6% of 
oligoastrocytomas grade II and grade III) but still lower than number of IDH1 mutations 
(68-82% oligoadendrogliomas grade II, 49-75% anaplastic oligodendrogliomas grade III, 50-
100% oligoastrocytomas, 63-100% anaplastic oligoastrocytomas grade III) (Bourne et al., 
2010). In addition the IDH1 R132C mutation is strongly associated with an astrocytoma 
phenotype (Hartmann et al., 2009).  
7.3 MGMT methylation status 
The DNA repair enzyme O-methylguanine-DNA methyltransferase (MGMT) removes alkyl 
groups from the O6 position resulting in an increased tumor resistance to alkylating agents 
therapy. Methylation of the MGMT promotor region results in decreased MGMT activity 
which in turn increases glioblastoma tumor cell sensivity to therapy with temozolomide and 
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is therefore a predictive molecular marker (Hegi et al., 2005). MGMT expression in tumor 
cells of astrocytomas and glioblastomas can be determined by nuclear  immunoreactivity of 
tumor cells (Capper et al., 2008). Together with other sophisticated methods such as realtime 
RT-PCR or methylation-specific pyrosequencing, they lack a valid definition for clinically 
relevant cut-off values (von Deimling et al., 2010). Usually MGMT is determined in 
formalin-fixated paraffin-embedded specimens through methylation-specific PCR, yet 
reliability and reproducibility are still limited in the current standard method (Preusser, et 
al., 2008b, Elezi et al., 2008). Not only is MGMT protein expression within tumors 
heterogenous, but also highly dependent on the method used and changes during therapy 
(Jung et al., 2010, Preusser et al., 2008a, Janzer et al., 2008). Thus reports on MGMT 
methylation range from 93% in frozen tissue sections in diffuse astrocytoma grade II 
(Everhard et al., 2006) to 30-35% in glioblastoma paraffin blocks (Tabatabai et al., 2010). In 
pediatric glioblastomas approximately half of the tumors are methylated (Srivastava et al., 
2010). Despite these shortcomings MGMT analysis is essential for almost all clinical studies 
and one of the most requested molecular analysis in neuropathology routine practice. 
7.4 Loss of 1p/19q 
A loss of heterozygosity is usually assessed though use of microsatellite marker PCR. This 
method requires corresponding blood samples to determine allele status. Therefore use of 
fluorescent in situ hybridisation is preferred by some laboratories but carries the risk of 
misdiagnosing cases with only partial loss. This risk can be covered by additional PCR that 
contains several loci along the chromosomal arms (Riemenschneider et al. 2010).  
Loss of heterozygosity in 1p and 19q are found in 78% of oligodendrogliomas grade II, 44% 
of oligoastrocytomas and 17% of diffuse astrocytomas grade II WHO. Therefore 1p19q 
codeletion is strongly associated with a oligodendroglial tumor morphology and often used 
as a diagnostic marker. In addition in oligodendrogliomas up to 73% of codeleted tumors 
also show either additional IDH1 or IDH2 mutations (Kim et al., 2010). Not surprisingly 
journal reviewers often require 1p19q deletions in oligodendrogliomas for sample 
homogeneity.  
8. Prognostic implications 
8.1 Immunohistochemistry 
Generally, tumor grade increases with age and younger age of onset is one of the strongest 
predictive factor of prolonged survival (Kita et al., 2009) and thus heavily influences all 
other markers found. Despite this fact, many publications do not take patients age into 
account when analyzing biomarkers on patient survival. In astrocytomas, MIB-1 
proliferation values above 5% are considered to be associated with a shorter survival (Jaros 
et al., 1992). Because of study population heterogeneity, predictive data on Tp53 mutations 
are limited. Some authors see p53 immunoreactivity to be associated with a shorter survival 
or shorter time to malignant progression (Jaros et al., 1992, Ständer et al., 2004). It is 
noteworthy, that not all p53 immunoreactive tumors contain mutations in the TP53 gene 
(Kösel et al., 2001). Further contrasting to immunohistochemistry data, a molecular study on 
159 grade II astrocytomas and oligoastrocytomas did not found an influence on overall 
survival, but reported a significant shorter progression-free survival (Peraud et al., 2002). In 
glioblastomas p53 mutation status does not correlate with patients outome (Weller et al., 
2009). Thus, p53 is only useful as a diagnostic marker but not prognostic. 
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8.2 Molecular biology 
Patients with IDH1/2 mutations in anaplastic astrocytomas and glioblastomas are usually 
younger than those lacking a IDH mutation (Nobusawa et al., 2009, Hartmann et al., 2009). 
In addition IDH1 mutations are a prognostic marker of favorable outcome in grade III and 
IV tumors (Yan et al., 2009, Nobusawa et al., 2009, Sanson et al., 2009). There is even a study 
demonstrating that IDH1-positive glioblastomas WHO grade IV have a better prognosis 
than IDH1-negative anaplastic astrocytomas WHO grade III (Hartmann et al., 2010). In 
contrast patients with IDH1 mutations in diffuse astrocytomas grade II WHO are older (Kim 
et al., 2010) or show at least a similar age distribution (Balss et al., 2008). The prognostic role 
of IDH1 in grade II diffuse astrocytomas is still to be determined. Sanson and colleagues 
found IDH1 to be an independent prognostic factor for longer survival in 100 samples 
(Sanson et al., 2009), while Kim et al. in 174 grade II tumors did not observe a more 
favorable outcome (Kim et al., 2010). So far IDH tumor status has not been incorporated into 
any current therapeutic trials but is likely to be included in the future.  
Analysis of low-grade astrocytomas did not found any association with MGMT promoter 
methylation and overall survival (Komine et al., 2003). In anaplastic gliomas, MGMT 
promoter hypermethylation is associated with longer progression free survival (Wick et al., 
2009). In glioblastomas, MGMT methylation status in addition as a marker of prolonged 
survival is a predictor to therapy response (Hegi et al., 2005). In oligodendroglial tumors 
there is a strong association between MGMT promoter methylation and 1p19q codeletion 
the latter also contributing to the improved survival of patients with MGMT methylation 
(Levin et al., 2006; Kesari et al., 2009). MGMT alone is useful as a prognostic marker but not 
useful to predict outcome of adjuvant treatment in oligodendrogliomas (van den Bent et al., 
2009).  
In oligodendrogliomas 1p19q codeletion is associated with improved survival (Jeon et al., 
2007, McLendon et al., 2005). Presence of oligodendroglial histopathology and 1p19q 
deletetion shows a better overall survival for anaplastic oligodendrogliomas treated  with 
radiation and PCV chemotherapeutic regimen (Giannini et al., 2008). The same study also 
demonstrated that 1p19q deletion alone is associated with a longer progression-free survival 
but that this effect is independent of initial treatment of oligodendrogliomas and mixed 
oligoastrocytomas (van den Bent et al., 2006). There is an inverse correlation with p53 
mutation and codeletion of chromosomal arms 1p and 19q in oligodendrogliomas 
implicating that oligodendrogliomas harbouring a Tp53 mutation have a reduced overall 
survival (Jeon et al., 2006, McLendon et al., 2005).  
In 9% of astrocytomas grade II WHO no common genetic alterations are detected (Kim et al., 
2010). In small biopsy specimen these tumors may enter the differential diagnosis of 
pilocytic astrocytoma. The latter often show BRAF abnormalities, wich drive MAPK 
pathway activation (Cin et al., 2011) but are absent in diffuse astrocytoma (Korshunov  et al., 
2009). Another possible differential diagnosis to low-grade diffuse astrocytoma is 
ganglioglioma and pleomorphic xanthoastrocytoma which in addition to their unique 
histological properties also exhibit BRAF V600E mutations, at present not known to be in 
diffuse astrocytomas (Schindler et al., 2011). 
9. Conclusion  
Histological classification of diffuse gliomas based on the WHO grading scheme is a 
prerequisite to optimal patient treatment decisions. Clinicians need to be aware that 
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diffuse gliomas form a histological continuum and that the four-tiered scores introduces a 
somewhat artificial separation. Tumors on the edge between grade II and III lesions 
behave different than tumors showing beginning endothelial proliferations indicating 
close progression to grade IV. A panel of different antibodies is very helpful to secure the 
diagnosis and avoids potential differential diagnosis pitfalls. Immunohistochemistry has 
also shown that several antibodies show divergent expression patterns. Researchers 
therefore should strive to clearly delineate between astrocytomas, oligodendrogliomas 
and oligoastrocytomas, when examining new biomarkers. Primary and secondary 
glioblastomas  are another example of “convergent evolution showing a similar 
phenotype of genotypically different tumor cells” (Basanta et al., 2011). The distinction of 
primary and secondary glioblastomas does not immediately influence management 
decisions, but because of their different genetic profile, it is expected that they may also 
differ in response to experimental therapies. Recent years have seen a progress in 
supplementing histological diagnosis of diffuse gliomas with an increasing spectrum of 
molecular markers. The utility of MGMT and 1p/19q in predicting response to therapy 
has led to their inclusion in current clinical trials. Implementation of these markers into 
routine diagnostic setting is expected after further successful results. Especially in 
oligoastrocytomas they complement histological results and provide a more objective 
classification. However clear cut-off levels for each assay is needed to guarantee 
interlaboratory compatibility. Histological control of the tissue used for molecular 
neuroonclogy through (neuro)pathologists is indispensable to avoid false-negative test 
results. Determining IDH1 status in diffuse gliomas is of diagnostic and clinical relevance. 
Not only indicates equal presence of IDH mutations a likely common origin of 
astrocytomas and oligodendrogliomas,  but also the strong prognostic role in high-grade 
gliomas is likely to be included in future revisions of the current WHO classification. 
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